The benefits of diversity in decision-making are well-documented. Having different perspectives and expertise produces better outcomes. But those don’t necessarily surface during discussions. How can leaders and organizations get the most from diverse perspectives and enhance the quality of conversations to achieve the best decisions?
One pressing concern for pharmaceutical companies is how to effectively allocate scarce resources across projects in R&D pipelines. Professor Panos Markou shares insights on how competitors’ investments in drugs that treat the same disorder may reveal potentially useful information, which senior executives can use to improve chances of success.